Research programme: gentamicin derivatives - La Jolla

Drug Profile

Research programme: gentamicin derivatives - La Jolla

Alternative Names: LJPC 30Sa; LJPC 30Sb; LJPC-30S

Latest Information Update: 18 Aug 2015

Price : $50

At a glance

  • Originator Indiana University Research and Technology Corporation
  • Developer Indiana University Research and Technology Corporation; La Jolla Pharmaceutical Company; University of Alabama at Birmingham
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bacterial infections; Cystic fibrosis
  • Research Duchenne muscular dystrophy

Most Recent Events

  • 05 Aug 2015 La Jolla enters into two worldwide license agreements for the intellectual property rights of LJPC 30Sa and LJPC 30Sb for the treatment of Bacterial infections and rare genetic disorders, including Cystic fibrosis and Duchenne muscular dystrophy
  • 07 May 2015 Preclinical trials in Cystic Fibrosis and Bacterial Infections in USA (Parenteral)
  • 07 May 2015 Early research in Duchenne muscular dystrophy in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top